Objective:

To provide an overview of the FDA regulatory pathways for minimally invasive glaucoma surgery (MIGS) devices and their implications for adoption and reimbursement.

Approach:

Key Findings:

• Devices take significantly less time to reach approval than drugs, averaging 3 to 7 years for devices compared to 12 years for drugs.
• Class I devices require minimal review, Class II devices follow the 510(k) pathway demonstrating substantial equivalence, and Class III devices undergo rigorous PMA processes.
• PMA-approved devices typically have stronger evidence supporting their safety and effectiveness, which aids in reimbursement.

Interpretation:

Understanding the regulatory pathways is crucial for clinicians to navigate device adoption and reimbursement effectively, particularly as newer devices emerge.

Limitations:

• The discussion reflects a clinician's perspective and may not encompass all regulatory complexities.
• The reliance on existing literature may limit the scope of insights into current regulatory challenges.

Conclusion:

Stronger evidence, particularly from prospective randomized controlled trials, is essential for the future success of 510(k) devices in securing reimbursement.

Sources:

• Van Norman GA. Drugs, devices, and the FDA: part 1
• Van Norman GA. Drugs, devices, and the FDA: part 2
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.